High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy

Lucillia Bezu; Guido Kroemer

doi:10.1080/2162402X.2024.2432059

High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy

Oncoimmunology. 2024 Dec 31;13(1):2432059. doi: 10.1080/2162402X.2024.2432059. Epub 2024 Nov 21.

Authors

Lucillia Bezu^{1

2

3

4}, Guido Kroemer^{1

2

5}

Affiliations

¹ Equipe labellisée par La Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
² Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France.
³ Département d'Anesthésie, Chirurgie et Interventionnel, Gustave Roussy, Villejuif, France.
⁴ EuroPeriscope, ESA-IC Onco-Anesthesiology Research Group (ESAIC_RG_EP), Brussels, Belgium.
⁵ Pôle de Biologie, Hôpital européen Georges Pompidou, AP-HP, Paris, France.

Abstract

Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.

Keywords: Biomarker; PD-1 blockade; cancer; chemotherapy; immunotherapy.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Biomarkers, Tumor / blood
Dacarbazine / administration & dosage
Dacarbazine / therapeutic use
Doxorubicin / administration & dosage
Doxorubicin / therapeutic use
HMGB1 Protein* / blood
Humans
Immunogenic Cell Death / drug effects
Immunotherapy / methods
Leiomyosarcoma* / blood
Leiomyosarcoma* / drug therapy
Leiomyosarcoma* / pathology
Nivolumab / administration & dosage
Nivolumab / therapeutic use
Prognosis

Substances

HMGB1 Protein
HMGB1 protein, human
Doxorubicin
Biomarkers, Tumor
Nivolumab
Dacarbazine

Grants and funding

G.K.is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)– Projets blancs; AMMICa US23/CNRS UMS3655; ARC; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); adonation by Elior; Equipex Onco-Pheno-Screen [ANR 21-ESRE-0028]; European Joint Programme on Rare Diseases (EJPRD); European Research Council Advanced Investigator Award [ERC-2021-ADG, ICD-Cancer, Grant No.101052444], European Union Horizon 2020 Projects Oncobiome, Prevalung (grant No.101095604) and Crimson [No.101016923]; Fondation Carrefour; INCa; Institut Universitaire de France; LabEx Immuno-Oncology [ANR-18-IDEX-0001]; a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). L.B.is supported by Société Française d’Anesthésie Réanimation (SFAR), La Ligue contre le Cancer, The Monahan Foundation, The Philippe Foundation.